Abstract
Objectives
We set out to create Consensus Guidelines, based on current evidence and
relative risks of adverse effects and the costs of different treatments,
that reflect the views of the British Rhinological Society (BRS) Council
on where the use of biologics should be positioned within treatment
pathways for CRSwNP, specifically in the setting of the National Health
Service (NHS).
Design
An expert panel of 16 members was assembled. A review of the literature
and evidence synthesis was undertaken and circulated to the panel We
used the RAND/UCLA methodology with a multi-step process to make
recommendations on the use of biologics.
Setting N/A
Participants N/A
Results
Recommendations were made, based on underlying disease severity, prior
treatments and co-morbidities. A group of patients for whom biologics
were considered an appropriate treatment option for CRSwNP was defined.
Conclusions
Although biologics are not currently available for the treatment of
CRSwNP, the BRS Council have defined a group of patients who have higher
rates of ‘failure’ with current treatment pathways, higher resource use
and are more likely to suffer with uncontrolled symptoms. We would urge
NICE to consider approval of biologics for such indications without
applying further restrictions on use.